GE HealthCare
(Nasdaq: GEHC)
today announced a partnership with Medis Medical Imaging to advance coronary artery disease (CAD) care.
The companies aim to advance precision care in the diagnosis and treatment of CAD. Together, they plan to further the development and commercialization of the Medis Quantitative Flow Ratio (QFR). This non-invasive approach to assessing coronary physiology now joins GE HealthCare’s interventional cardiology portfolio around the Allia Platform.
According to a news release, the companies expect the collaboration to provide access to emerging technologies like Medis QFR. At the same time, the intend to reduce complexity in the cath lab and improve the operating environment for clinicians.
GE HealthCare said it wants to bring Medis QFR to clinicians as an emerging, non-invasive, image-based diagnostic approach to both assessing coronary artery physiology and treating CAD. A recent study of QFR guidance demonstrated improved two-year clinical outcomes, the company said. That included a reduction in myocardial infarction and ischemia-driven revascularization when compared to standard angiography guidance alone.
“We continue to see an evolution in how clinicians work to treat cardiovascular disease and want to give clinicians the tools, along with the flexibility and adaptability, they need to enable better outcomes for their patients,” said Arnaud Marie, GM for global intervention at GE HealthCare. “In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights. We’re excited to collaborate with Medis Medical Imaging to add innovative, non-invasive, image-based QFR to our portfolio of offerings around our Allia IGS platform to streamline the experience for clinicians and help us to deliver on our vision for the future image-guided therapy.”
More about the Medis Medical Imaging technology coming to the GE HealthCare portfolio
Medis QFR, a proprietary solution, delivers image-based physiology of coronary obstructions. It bases this on angiography imaging analysis alone. With it, interventional cardiologists can effectively and efficiently determine if percutaneous coronary intervention (PCI) is required or if treatment should be deferred.
If a patient requires treatment, QFR can help clinicians select the lesions for treatment and create a plan. That could lead to a balloon- or stent-based PCI procedure and help the clinician evaluate the treatment’s efficacy. They can also perform the analysis in real-time with the patient on the table.
GE HealthCare said this technology enhances its portfolio, optimizing workflows, unlocking efficiencies and driving better patient outcomes.
“We are absolutely delighted to be taking this next step with GE HealthCare, a fellow leader in the interventional cardiology domain,” shares Maya Barley, CEO of Medis Medical Imaging. “Building on Medis QFR’s decade of AI research, customer-focused product development, clinical evidence generation and business development, we are excited to be able to further accelerate our efforts around Medis QFR to enable more hospitals and clinicians to apply physiology in day-to-day interventional practice a part of best-practice clinical care – making this technology more accessible and available to patients than ever before.”
